Cancer remains a formidable global health challenge, necessitating innovative therapeutic strategies. Traditional small-molecule inhibitors often face limitations in selectively targeting disease associated proteins, leading to side effects and incomplete therapeutic responses. Proteolysis targeting chimeras (PROTACs) have emerged as a promising approach to address these challenges. Unlike traditional inhibitors, PROTACs leverage the cellular ubiquitin-proteasome system to selectively degrade disease-associated proteins. In this review, we discuss PROTACs as a targeted approach for cancer management, highlighting key findings, limitations, and future perspectives. For this, the authors have critically reviewed literature obtained from prime sources comprising Google Scholar, Web of Science, PubMed, and Publons. Additional relevant articles were retrieved from the reference sections of selected papers. Preclinical studies and early-phase clinical trials have demonstrated the efficacy and potential of PROTACs in cancer management. Additionally, the potential of PROTACs in overcoming therapy resistance, tackling tumor heterogeneity, and engaging multiple pathways is explored. As research advances, addressing challenges and refining PROTAC technology will pave the way for their integration into the next generation of cancer therapeutics, marking a transformative era in precision medicine.

Background: In this paper, we have discussed recent advances in our understanding of the aetiology of psoriasis, particularly as they relate to aryl hydrocarbon receptors in DCs, Langerhans cells, macrophages, signal transducer and activator of transcription 3 pathways, and dermal vascular endothelial cells. Here, we have shown that the ability to target specific cellular and molecular components of psoriasis pathogenesis with nanoscale precision using phos-phodiesterase 4 inhibitors represents a transformative opportunity to address the complex nature of this dermatological condition. Objective: In this review, we have examined the molecular mechanisms behind the pathogenic features of psoriasis and new treatments being tested in clinical settings. There is research being done on new treatments created in the last ten years. This field highlights the advantages of nan-otechnological technologies as cutting-edge candidates for drug delivery systems in psoriasis and other inflammatory chronic skin disorders. Future Developments: Nanotechnology-based treatments currently under study show good effi-cacy and low side effect profiles. However, long-term prospective trials are required to demon-strate long-term safety and effectiveness. Phosphodiesterase inhibitors, Janus kinase inhibitors, nonsteroidal anti-inflammatory drugs, combinations of vitamin D3 derivatives and corticoster-oids, and coal tar formulations are some of the newer topical treatments for psoriasis. Conclusion: The psoriasis treatment continues to involve conventional medications (i.e., medi-cines that are generally acknowledged as either normal therapy or outdated remedies), whether used topically or orally. Nonetheless, we are starting to see initiatives to create pharmaceuticals and biosimilars with better therapeutic results, fewer side effects, and greater efficacy

Background Artificial intelligence (AI) has become a novel approach for bioactive molecule search, target identification, prediction of lead molecule-target interaction, design of pharmaceutical formulations, and efficient conduction and prediction of results of clinical trials. Main body AI has revolutionized the drug discovery and pharmaceutical product development. Traditional methods are time-consuming and costlier due to large experimentation number and low hit and success. Herein, AI can analyse a large dataset quickly to give possible outcomes. AI easily identifies potential drug targets by virtual screening of biological data, resulting in time-efficient and low-cost discovery of novel drug targets. AI can be used for the design of new drug candidates by analysing the possible molecular structures binding with targets. Moreover, AI can easily predict drug interactions with targets to exert therapeutic action. AI-enabled drug repurposing is based on the interaction of existing drugs with new targets or other explored target datasets. AI can play prominent role in accelerating the development of pharmaceutical products due to their role in optimization and process validation. The clinical trials have also become easy and faster with use of AI tools. Conclusion Artificial Intelligence based tool can be employed in discovery of lead molecule, target identification, drug-target interaction, development of pharmaceutical product and clinical trials to accelerate the production of clinically acceptable therapeutics with higher success rate.

The present work deals with the development of a novel co-processed excipients using melt- granulation technique that would serve as an inbuilt multifunction adjuvant and can be used for the preparation of tablet as solid dosage form with poorly compressible drugs like Paracetamol, Diclofenac, and Ibuprofen etc. by direct compression method. In the formulation DCP (Dicalcium phosphate) and Potato Starch were used as a filler in 2:1 ratio; Croscarmellose as a superdisintegrant and 20% w/v PEG 6000 (polyethylene glycol) as a binder, to develop the co-processed excipient. This resulted in formation of co-processed agglomerates, which had exhibited better flowability, compressibility and compaction properties when compared to an individual excipient and/or the physical mixture of compounds. Being a poorly compressible drug, PCM (Paracetamol) was used as a model drug to prepare tablets. The finally developed tablet dosage form of PCM along with co-processed excipient, were subjected to Fourier Transform Infra-Red (FTIR) study to ensure the absence of any drug-excipient interaction. The dosage form was also evaluated for capping and lamination to assure the better compressibility profile. The surface characteristics of developed co-processed agglomerated mass was characterised using Scanning Electron Microscopy (SEM). From the results obtained, it was concluded that the co-processed excipient is superior in flowability and compression characteristics in comparison to the physical mixture of excipients and individual components both. FTIR studies explained that there is no drug-excipient interaction and SEM also shown the spherical shapes of the agglomerated mass proving the better flowability properties of co-processed excipients.

Alzheimer’s disease is a degenerative neurological condition mostly affecting memory and cognitive abilities in older people. This study aimed to determine how acteoside, a major plant phytoconstituent, protects against neuronal death in the hippocampus region, activates the cholinergic system, and acts as an antioxidant to help people with Alzheimer’s-type dementia. Early research on the extraction process and subsequent in vitro testing revealed that the plant extract had potent antioxidant qualities. Initial assessment highlighted the yield percentage, which was 14.10% using the Soxhlet method. In order to explore this plant’s possible medical uses, further in vivo studies are required.